Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Silence Therapeutics plc NASDAQ:SLN | $936.65M | $19.83 | Not rated | -3.9 | +193.63% |
Capricor Therapeutics, Inc. NASDAQ:CAPR | $551.90M | $9.53 | Not rated | -13.9 | +42.38% |
Lyell Immunopharma, Inc. NASDAQ:LYEL | $351.57M | $14.30 | Not rated | -1.1 | -22.53% |
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM | $348.58M | $9.86 | Not rated | -7.5 | -19.72% |
Atea Pharmaceuticals, Inc. NASDAQ:AVIR | $345.31M | $4.30 | Not rated | -2.0 | +30.82% |
Editas Medicine, Inc. NASDAQ:EDIT | $334.92M | $2.17 | Not rated | -2.4 | -32.44% |
Allogene Therapeutics, Inc. NASDAQ:ALLO | $290.58M | $0.84 | Not rated | -2.7 | -46.88% |
Cabaletta Bio, Inc. NASDAQ:CABA | $276.12M | $1.28 | Not rated | -1.8 | -54.91% |
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | $235.59M | $2.87 | Not rated | -4.6 | -67.86% |
Mereo BioPharma Group plc NASDAQ:MREO | $49.10M | $0.31 | Not rated | -1.4 | -82.42% |
Continue the stock analysis
Jump to another research area for this company.